NOWDiagnostics

12/25/2025

NOWDx sincerely wishes you a very merry and meaningful Christmas holiday.

12/24/2025

Syphilis rates are still at epidemic levels in the US – it's more important than ever for sexually active individuals to test to determine their syphilis status.

Take control of your health or help someone you care about with the First To Know® Syphilis Test—a new in-home blood test that delivers accurate results in just 15 minutes. It’s the perfect gift for privacy, confidence, and peace of mind this season.

👉 To learn more and order your test today visit https://bit.ly/4pdjRKS

12/22/2025

Hello everyone,

We’re pleased to announce that Dr. Hazim Aljewari has been promoted to Director of R&D, Molecular Biology.

Since joining NOWDiagnostics®, Hazim has made immediate and meaningful contributions to our lab operations and molecular diagnostics program.

Before NOWDx, Hazim spent several years at the University of Arkansas, where his work focused on molecular biology, biotechnology, genetics, and bioprocessing engineering. His strong translational research background allowed him to transition quickly into NOWDx and take on an early leadership role in molecular assay development.

Hazim brings over a decade of research experience, with three patents and more than 50 peer-reviewed publications. He also has a broad international background, including research at Khon Kaen University in Thailand and an academic career in Iraq as an Assistant Professor at the University of Baghdad, where he also founded an international lab supply company.

At NOWDx, Hazim has already played a key role in advancing proprietary molecular assays and solving polymerase inactivity in saliva—work now being captured as a provisional patent. His team’s dedication was clear when they worked through the Thanksgiving weekend to resolve critical reagent issues.

The molecular program is central to NOWDx’s value, and Hazim’s leadership continues to strengthen it. He is a natural teacher and collaborator who brings great energy to the team. In his new role, Hazim will lead the day-to-day activities of the molecular group and report directly to Dr. Jody Berry, Chief Scientific Officer.

Please join us in congratulating Dr. Hazim Aljewari on his well-deserved promotion.

12/15/2025

NOWDiagnostics (NOWDx) Welcomes Nate Fecik as Our Newest Public Health Account Executive

We are pleased to announce that Nathan “Nate” Fecik has joined NOWDiagnostics as our newest Public Health Account Executive.

Nate comes to NOWDx with extensive experience in federal public health service. Most recently, he served as a Senior Public Health Advisor for Syndemics and Co-Principal for the Sexually Transmitted Infections portfolio within the Office of Infectious Disease and HIV/AIDS Policy (OIDP), Office of the Assistant Secretary for Health (OASH), U.S. Department of Health and Human Services (HHS) in Washington, D.C.

In this role, Nate led the development of a new syndemics policy and strategic planning portfolio aimed at centering communities and addressing shared determinants of HIV, STIs, viral hepatitis, substance use, and mental health disorders. His work included facilitating a cross-agency, multidisciplinary working group to advance this integrated approach.

Nate will assume responsibilities for promoting the First To Know® Syphilis Tests in all Public Health markets throughout the United States.

Please join us in welcoming Nate to his new role at NOWDiagnostics.

10/31/2025

Syphilis is sometimes called the “great imitator” because its symptoms can look like many other conditions — or may not show up at all. That’s why regular testing is so important to protect our communities.

With the First To Know® Syphilis Test, individuals can take control of their health right at home, and get reliable results in only 15 minutes.

Learn more: https://bit.ly/3VCpt4Z

10/31/2025

🎃👻 Happy Halloween from all of us at NOWDx! 🧡🦇
Wishing you a safe and fun night filled with treats (no tricks). 🍬

10/30/2025

10/23/2025

According to the CDC, syphilis remains a serious public health issue. In 2023, the U.S. saw 209,253 total syphilis cases. While primary & secondary syphilis dropped ~10% from 2022 to 2023, late-stage cases rose ~12.8%.

Why this matters: untreated syphilis can lead to severe health problems even years later.

Learn how testing can catch syphilis early: https://bit.ly/3IJDvPg.
Learn more about congenital syphilis: https://bit.ly/471Qghq

10/22/2025

According to the JAMA Network, Nearly 90% of congenital syphilis cases could have been prevented with proper prenatal care, timely testing, and treatment. Many pregnant women either don’t get prenatal care early enough, aren’t tested, or don’t receive treatment.

You have power over prevention — ask for syphilis testing early in pregnancy.

👉 Learn more at https://bit.ly/4nKY0up.

10/16/2025

Why wait for peace of mind?

The First To Know® Syphilis Test makes it fast and easy to screen at home—with results in minutes. Protect yourself, protect your partners, and stay informed.

Get yours today or learn more: https://bit.ly/42keReO.

10/15/2025

October 15 is National Latinx AIDS Awareness Day.

HIV and syphilis are syndemic—meaning they often occur together and fuel each other’s spread. Protecting your health means staying informed, getting tested, and knowing your status.

The First To Know® Syphilis Test is the first and only FDA-authorized in-home syphilis self-test, delivering accurate results in just 15 minutes.

Learn more: https://bit.ly/3W0IqP3.

Let’s stand together to promote testing, and support the Latinx community in achieving healthier futures.

10/09/2025

Penicillin remains the first-line treatment for all stages of syphilis and the only option in some cases. Delaying treatment can lead to serious long-term effects — but early diagnosis + timely treatment can prevent nearly all complications.

👉 If your First To Know® Syphilis Test is positive, don’t wait — visit https://bit.ly/4nJLknu to connect with a healthcare provider.